Enhanced Expression of CD47 Is Associated With Off-Target Resistance to Tyrosine Kinase Inhibitor Gefitinib in NSCLC

Mutual interactions between cancer cells and the tumor microenvironment importantly contribute to the development of tyrosine kinase inhibitor (TKI) resistance in patients affected by EGFR-mutant NSCLC. In particular, immune recognition-associated proteins with impact on tumor cell clearance through phagocytosis, such as CD47 and calreticulin, could contribute to adaptive resistance and immune escape. Preclinical studies targeting the anti-phagocytic CD47 molecule showed promising results in different cancer types including lung cancer, but no data are available on its role in patients acquiring resistance to EGFR TKI treatment. We analyzed the functional contribution of CD47 and calreticulin to immune surveillance and evasion in a panel of NSCLC cell lines carrying sensitizing or resistant mutations in the EGFR gene, following treatment with the TKI gefitinib and after in vitro development of gefitinib resistance. While CD47 and calreticulin protein levels were markedly variable in both EGFR-mutant and wild-type cell lines, analysis of NSCLC transcriptomic dataset revealed selective overexpression of CD47 in patients carrying EGFR mutations. EGFR inhibition significantly reduced CD47 expression on the surface of pre-apoptotic cells, favoring more efficient engulfment of cancer cells by monocyte-derived dendritic cells. This was not necessarily associated with augmented surface exposure of calreticulin or other molecular markers of immunogenic cell death. Moreover, CD47 expression became up-regulated following in vitro drug resistance development, and blocking of this protein by a specific monoclonal antibody increased the clearance of EGFR-TKI resistant cells by phagocytes. Our study supports CD47 neutralization by specific monoclonal antibody as a promising immunotherapeutic option for naïve and resistant EGFR-mutant NSCLCs.

[1]  Betty Y. S. Kim,et al.  Phagocytosis checkpoints as new targets for cancer immunotherapy , 2019, Nature Reviews Cancer.

[2]  A. Drilon,et al.  Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  N. Girard,et al.  Advanced-Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  S. Hohaus,et al.  Clinical and Antitumor Immune Responses in Relapsed/Refractory Follicular Lymphoma Patients after Intranodal Injections of IFNα-Dendritic Cells and Rituximab: a Phase I Clinical Trial , 2019, Clinical Cancer Research.

[5]  L. Zitvogel,et al.  Author Correction: Crizotinib-induced immunogenic cell death in non-small cell lung cancer , 2019, Nature Communications.

[6]  J. Ahn,et al.  Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma , 2019, Journal of Cancer Research and Clinical Oncology.

[7]  Yi-long Wu,et al.  Strong Programmed Death Ligand 1 Expression Predicts Poor Response and De Novo Resistance to EGFR Tyrosine Kinase Inhibitors Among NSCLC Patients With EGFR Mutation , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[8]  E. Vasile,et al.  Italian Nivolumab Expanded Access Program in Nonsquamous Non–Small Cell Lung Cancer Patients: Results in Never‐Smokers and EGFR‐Mutant Patients , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  A. Investigators.  Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study , 2018 .

[10]  In Seok Yang,et al.  Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs. , 2017, Lung cancer.

[11]  T. Bivona,et al.  Understanding and targeting resistance mechanisms in NSCLC , 2017, Nature Reviews Cancer.

[12]  V. Adamo,et al.  Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going. , 2017, Critical reviews in oncology/hematology.

[13]  A. Weisz,et al.  Exploiting a new strategy to induce immunogenic cell death to improve dendritic cell-based vaccines for lymphoma immunotherapy , 2017, Oncoimmunology.

[14]  K. Weiskopf.  Cancer immunotherapy targeting the CD47/SIRPα axis. , 2017, European journal of cancer.

[15]  Lin F. Yang,et al.  Anti-CD47 Antibody As a Targeted Therapeutic Agent for Human Lung Cancer and Cancer Stem Cells , 2017, Front. Immunol..

[16]  Yubin Li,et al.  Targeting CD47 and Autophagy Elicited Enhanced Antitumor Effects in Non–Small Cell Lung Cancer , 2017, Cancer Immunology Research.

[17]  K. Tsang,et al.  Short-term EGFR blockade enhances immune-mediated cytotoxicity of EGFR mutant lung cancer cells: rationale for combination therapies , 2016, Cell Death and Disease.

[18]  J. Kattan,et al.  Adding checkpoint inhibitors to tyrosine kinase inhibitors targeting EGFR/ALK in non-small cell lung cancer: a new therapeutic strategy , 2016, Investigational New Drugs.

[19]  W. Hong,et al.  Immune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung Cancer , 2016, PloS one.

[20]  Zhijie Kang,et al.  CD47 Promotes Tumor Invasion and Metastasis in Non-small Cell Lung Cancer , 2016, Scientific Reports.

[21]  I. Weissman,et al.  CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. , 2016, The Journal of clinical investigation.

[22]  A. Bardelli,et al.  The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death , 2016, Nature Medicine.

[23]  R. Doebele,et al.  A framework for understanding and targeting residual disease in oncogene-driven solid cancers , 2016, Nature Medicine.

[24]  G. Kroemer,et al.  Calreticulin Expression in Human Non-Small Cell Lung Cancers Correlates with Increased Accumulation of Antitumor Immune Cells and Favorable Prognosis. , 2016, Cancer research.

[25]  J. Chen,et al.  CD47: a potential immunotherapy target for eliminating cancer cells , 2016, Clinical and Translational Oncology.

[26]  O. Arrieta,et al.  Interplay between Cellular and Molecular Inflammatory Mediators in Lung Cancer , 2016, Mediators of inflammation.

[27]  Y. Cho,et al.  Crosstalk with cancer-associated fibroblasts induces resistance of non-small cell lung cancer cells to epidermal growth factor receptor tyrosine kinase inhibition , 2015, OncoTargets and therapy.

[28]  Y. Oya.  3075 Association between clinical outcome of first EGFR-TKIs and T790M mutation in NSCLC patients harboring EGFR mutation with acquired resistance to EGFR-TKIs , 2015 .

[29]  M. Delorenzi,et al.  Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy , 2014, Nature Medicine.

[30]  Eric Bender,et al.  Epidemiology: The dominant malignancy , 2014, Nature.

[31]  P. Vandenabeele,et al.  Consensus guidelines for the detection of immunogenic cell death , 2014, Oncoimmunology.

[32]  T. K. van den Berg,et al.  The interaction between signal regulatory protein alpha (SIRPα) and CD47: structure, function, and therapeutic target. , 2014, Annual review of immunology.

[33]  Travis J Cohoon,et al.  Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. , 2013, Cancer discovery.

[34]  Tinghong Ye,et al.  Enhanced interaction between natural killer cells and lung cancer cells: involvement in gefitinib-mediated immunoregulation , 2013, Journal of Translational Medicine.

[35]  William Pao,et al.  Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers , 2013, Clinical Cancer Research.

[36]  Masao Nagasaki,et al.  Epidermal Growth Factor Receptor Tyrosine Kinase Defines Critical Prognostic Genes of Stage I Lung Adenocarcinoma , 2012, PloS one.

[37]  I. Weissman,et al.  The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications. , 2012, Current opinion in immunology.

[38]  Jens-Peter Volkmer,et al.  The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors , 2012, Proceedings of the National Academy of Sciences.

[39]  Zoltan Szallasi,et al.  Jetset: selecting the optimal microarray probe set to represent a gene , 2011, BMC Bioinformatics.

[40]  L. E. Fernández,et al.  Induction of Immunogenic Apoptosis by Blockade of Epidermal Growth Factor Receptor Activation with a Specific Antibody , 2011, The Journal of Immunology.

[41]  Sun-Hee Kim,et al.  EGFR Inhibitors Enhanced the Susceptibility to NK Cell-mediated Lysis of Lung Cancer Cells , 2011, Journal of immunotherapy.

[42]  N. Altorki,et al.  TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer , 2010, Proceedings of the National Academy of Sciences.

[43]  I. Weissman,et al.  CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis , 2009, Cell.

[44]  W. Zou,et al.  CD47 regulates bone mass and tumor metastasis to bone. , 2009, Cancer research.

[45]  Ping Yang,et al.  Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. , 2008, Mayo Clinic proceedings.

[46]  P. van Endert,et al.  Ecto‐calreticulin in immunogenic chemotherapy , 2007, Immunological reviews.

[47]  M. Tsuboi,et al.  Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib , 2006, Clinical Cancer Research.

[48]  E. Brown,et al.  Integrin-associated protein (CD47) and its ligands. , 2001, Trends in cell biology.

[49]  C. Lagenaur,et al.  Role of CD47 as a marker of self on red blood cells. , 2000, Science.

[50]  Keunchil Park,et al.  Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. , 2018, The Lancet. Oncology.

[51]  Satoru Miyano,et al.  Identification of genes upregulated in ALK-positive and EGFR/KRAS/ALK-negative lung adenocarcinomas. , 2012, Cancer research.

[52]  F. Belardelli,et al.  IFN-alpha in the generation of dendritic cells for cancer immunotherapy. , 2009, Handbook of experimental pharmacology.